Coronis Research
Coronis Research is recorded as a service provider in 17 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 17 of 17 trials · Latest update first
Efficacy of Venetoclax in combination with Rituximab in Waldenström’s Macroglobulinemia
Sponsor University Hospital Of Ulm AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN : Randomised, international and multicentric phase 3 study that evaluates 3 therapeutic phases (induction, high-dose chemotherapy and radiotherapy) for patients with high-risk neuroblastoma, and introduces chemoimmunotherapy for patients with insufficient metastatic response after induction chemotherapy
Sponsor Institut Gustave Roussy
- Start (EU)
- Latest update
- Estimated end
Interfant-21: International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia
Sponsor Princess Maxima Center For Pediatric Oncology
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous of AB8939 in patients with Relapsed/Refractory Acute Myeloid Leukemia
Sponsor Ab Science
- Start (EU)
- Latest update
- Estimated end
- Not reported
Early oral step-down antibiotic therapy versus continuing intravenous therapy for uncomplicated Gram-negative bacteraemia (the INVEST trial)
Sponsor Tan Tock Seng Hospital Pte. Ltd.
- Start (EU)
- Latest update
- Estimated end
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
Sponsor GPOH gGmbH
- Start (EU)
- Latest update
- Estimated end
FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma
Sponsor The University Of Birmingham
- Start (EU)
- Latest update
- Estimated end
A Randomized Trial of the I-BFM-SG for the Management of Childhood non-mature-B Acute Lymphoblastic Leukemia
Sponsor Semmelweis University
- Start (EU)
- Latest update
- Estimated end
A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)
Sponsor Ab Science
- Start (EU)
- Latest update
- Estimated end
- Not reported
A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 Trial to compare the efficacy and safety of masitinib in combination with standard of care versus placebo in combination with standard of care in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)
Sponsor Ab Science
- Start (EU)
- Not reported
- Latest update
- Estimated end
A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the Treatment of Patients with Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse
Sponsor Ab Science
- Start (EU)
- Latest update
- Estimated end
- Not reported
International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents
Sponsor GPOH gGmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis
Sponsor St. Anna Childrens Cancer Research Institute GmbH
- Start (EU)
- Latest update
- Estimated end
Randomized, double-blind, parallel-groups, active - and placebo-controlled study to Evaluate the efficacy of a fixed combination of diclofenac 75 mg + thiocolchicoside 4 mg as solution for injection, in reLIEving back pain symptoms. Controlled study vs. dicloFenac 75 mg solution for injection and placebo. RELIEF Study
Sponsor Epifarma S.r.l.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia - A MULTICENTER OPEN LABEL, SINGLE ARM EUROPEAN PHASE II STUDY (ECWM-2)
Sponsor University Hospital Of Ulm AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1)
Sponsor Universitaetsklinikum Ulm AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2 Study of the Efficacy and Safety of a Dose of Donor-Derived CD19-targeted CAR T cells for children and young adults (up to 39 years old) with recurrent or persistent CD19 (+) Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
Sponsor Nosokomeio Paidon I Agia Sofia
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Coronis Research?
The 2026-10-09 snapshot links Coronis Research to 17 distinct CTIS trials. Recorded services include Clinical monitoring, Regulatory services, Project management, Safety reporting & pharmacovigilance, among 10 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Coronis Research?
The most frequently recorded therapeutic areas are Haematological Malignancies, Solid Tumor Oncology, Infectious Disease. Recorded phases include Phase 3, Phase 2, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Coronis Research conducted?
The linked trials record locations in 22 countries, including Greece, Germany, Spain, France, Italy. These are trial locations, not confirmed office locations or countries where Coronis Research delivered services.
What can this page tell me about Coronis Research's trial experience?
Browse 17 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Coronis Research. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Coronis Research S.A.